Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449730 | 1.00 | ALDH1A1 (0.71) | ALDH1A1HPGDNOTUMTSHRNPC1 | |
| Hydrochloric Acid SCHEMBL10741975 | 0.98 | ALDH1A1 (0.69) | ALDH1A1HPGDNOTUMTSHRNPC1 | |
| SCHEMBL28092234 | 0.90 | ALDH1A1 (0.59) | ALDH1A1HPGDNOTUMTSHRNPC1 | |
| SCHEMBL29353444 | 0.89 | SMN1; SMN2 (0.77) | ALDH1A1HPGDNOTUMTSHRSMN1; SMN2 | |
| SCHEMBL2829456 | 0.89 | SMN1; SMN2 (0.77) | ALDH1A1HPGDNOTUMTSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11845665 | 0.87 | SMN1; SMN2 (0.74) | ALDH1A1HPGDNOTUMTSHRSMN1; SMN2 | |
| SCHEMBL30456228 | 0.87 | SMN1; SMN2 (0.69) | ALDH1A1HPGDNOTUMTSHRSMN1; SMN2 | |
| SCHEMBL29804966 | 0.86 | NOTUM (0.72) | ALDH1A1HPGDNOTUMTSHRNPC1 | |
| SCHEMBL5492978 | 0.86 | SMN1; SMN2 (0.79) | ALDH1A1HPGDNOTUMTSHRNPC1 | |
| SCHEMBL17117378 | 0.86 | NOTUM (0.72) | ALDH1A1HPGDNOTUMTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894327-A | Process for preparing indoline carboxylic ester | 阿拉善盟锦源科技发展有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-110256326-B | Indoline carboxylic acid alkaloid in purslane and extraction and separation method and application thereof | 辽宁中医药大学 | 2022-05-13 | — | — | CN | claimed |
| CN-112375028-A | Method for synthesizing (2S) -indoline-formic acid | 安徽美诺华药物化学有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-111646999-A | Indoline carboxylic acid compound and preparation method thereof | 内江师范学院 | 2020-09-11 | — | — | CN | claimed |
| CN-110256326-A | Indoline carboxylic acid alkaloid in purslane and extraction and separation method and application thereof | 辽宁中医药大学 | 2019-09-20 | — | — | CN | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| US-9328107-B2 | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| CN-103402511-B | New benzodioxole piperidine compounds | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | claimed |
| EP-2018371-B1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | claimed |
| US-6274594-B1 | ANTICONVULSANTS, ANALGESICS; NERUOPATHIC, CANCER AND DENTAL PAIN; | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-14 | — | — | US | claimed |
| US-6232305-B1 | ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | NAEJA PHARMACEUTICAL INC. (CA) | 2001-05-15 | — | — | US | claimed |
| EP-1032570-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2000-09-06 | — | — | EP | claimed |
| WO-1999025709-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-27 | — | — | WO | claimed |
| EP-0180544-B1 | PROCESS FOR THE PREPARATION OF A CARBOXYLIC ACID | CIBA-GEIGY AG (CH) | 1988-06-15 | — | — | EP | claimed |
| US-4595766-A | Process for the preparation of an indoline carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1986-06-17 | — | — | US | claimed |
| US-4479963-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | claimed |
| US-4374847-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-02-22 | — | — | US | claimed |
| EP-0051301-A1 | 1-Carboxy-azaalkyl-indolin-2-carboxylic acids, process for preparing them, pharmaceutical compositions containing them and their therapeutical use | CIBA-GEIGY AG (CH) | 1982-05-12 | — | — | EP | claimed |
| EP-0050850-A1 | 1-Carboxyalkanoylindolin-2-carboxylic acids and derivatives thereof, processes for their preparation, and pharmaceutical compositions containing these compounds | CIBA-GEIGY AG (CH) | 1982-05-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235622-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | ALDH1A1 953/4885HPGD 2403/4885NOTUM 2411/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | ALDH1A1 953/4885HPGD 2403/4885NOTUM 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.